A second BioZorb trial will begin in January 2026, and two additional claims will be set to go before juries at a later date, which could help drive settlement negotiations between the parties.
Plaintiffs sought to conduct additional discovery and depositions, as a small group of BioZorb recall lawsuits are being prepared for early trial dates expected to begin in September 2025.
Several studies published in recent years have suggested a link between the popular IUD Mirena and breast cancer, but more research is needed to enhance the relevance of these findings.
The women were left with intense pain and fears of the development of new tumors caused by BioZorb after undergoing breast cancer surgery.
Investigators found deficiencies in the manufacturer’s design process, the implantation procedure, and a failure to properly respond to complaints about BioZorb Marker problems in a timely manner.
As lawyers prepare for the first federal trials, the Judge presiding over the litigation indicates that the Court will not address pending motions for summary judgment that are unrelated to those bellwether cases.
Five women out of every 100 that drink more than two drinks per day will develop breast cancer, U.S. health officials warn.
All four plaintiffs are breast cancer survivors who say their BioZorb tissue marker implants failed to properly absorb into their bodies as advertised.
Doctors are being urged not to implant recalled BioZorb tissue markers in any new patients, and to closely monitor those who have received the implants.
Lawsuits allege recalled BioZorb Markers failed to absorb after breast cancer treatments, resulting in painful complications and need for additional surgery.
